Savant Capital LLC Has $3.06 Million Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Savant Capital LLC decreased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 10.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 7,547 shares of the medical research company’s stock after selling 860 shares during the period. Savant Capital LLC’s holdings in Thermo Fisher Scientific were worth $3,060,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the stock. Brighton Jones LLC boosted its stake in shares of Thermo Fisher Scientific by 28.9% in the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock valued at $2,293,000 after purchasing an additional 988 shares in the last quarter. Revolve Wealth Partners LLC lifted its holdings in Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after purchasing an additional 20 shares during the last quarter. Alps Advisors Inc. boosted its position in Thermo Fisher Scientific by 19.4% in the first quarter. Alps Advisors Inc. now owns 3,496 shares of the medical research company’s stock valued at $1,740,000 after buying an additional 568 shares in the last quarter. Kathmere Capital Management LLC grew its stake in Thermo Fisher Scientific by 15.9% during the first quarter. Kathmere Capital Management LLC now owns 982 shares of the medical research company’s stock worth $489,000 after buying an additional 135 shares during the last quarter. Finally, Stephens Inc. AR raised its stake in shares of Thermo Fisher Scientific by 3.8% in the first quarter. Stephens Inc. AR now owns 26,469 shares of the medical research company’s stock valued at $13,171,000 after acquiring an additional 963 shares during the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CEO Marc N. Casper sold 17,104 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, October 24th. The shares were sold at an average price of $573.54, for a total transaction of $9,809,828.16. Following the transaction, the chief executive officer owned 113,762 shares of the company’s stock, valued at $65,247,057.48. This trade represents a 13.07% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Gianluca Pettiti sold 400 shares of the company’s stock in a transaction that occurred on Friday, October 24th. The shares were sold at an average price of $574.15, for a total transaction of $229,660.00. Following the completion of the sale, the executive vice president directly owned 21,152 shares of the company’s stock, valued at $12,144,420.80. The trade was a 1.86% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 36,420 shares of company stock worth $19,980,884. Insiders own 0.33% of the company’s stock.

Wall Street Analysts Forecast Growth

TMO has been the topic of a number of research analyst reports. Royal Bank Of Canada set a $561.00 price target on Thermo Fisher Scientific and gave the stock an “outperform” rating in a research report on Tuesday, September 2nd. Robert W. Baird increased their target price on Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an “outperform” rating in a report on Thursday, July 24th. Citigroup lifted their price target on Thermo Fisher Scientific from $500.00 to $580.00 and gave the company a “neutral” rating in a report on Thursday, October 23rd. TD Cowen increased their price objective on shares of Thermo Fisher Scientific from $612.00 to $654.00 and gave the stock a “buy” rating in a report on Thursday, October 23rd. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Thermo Fisher Scientific in a research note on Thursday, October 23rd. Nineteen research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $601.65.

Thermo Fisher Scientific Trading Up 1.2%

TMO opened at $572.72 on Monday. The firm has a 50 day simple moving average of $518.58 and a 200 day simple moving average of $462.80. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $610.97. The company has a market cap of $215.18 billion, a price-to-earnings ratio of 33.09, a price-to-earnings-growth ratio of 3.27 and a beta of 0.82. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. The firm had revenue of $11.12 billion during the quarter, compared to analyst estimates of $10.90 billion. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The business’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $5.28 EPS. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific declared that its Board of Directors has initiated a stock repurchase plan on Thursday, November 6th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical research company to buy up to 2.4% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s leadership believes its shares are undervalued.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, January 15th. Shareholders of record on Monday, December 15th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Monday, December 15th. This represents a $1.72 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is presently 9.94%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.